NanoVibronix Files 8-K with Corporate Details

TL;DR

NVBX filed an 8-K on Jan 6, 2025, confirming HQ address in Tyler, TX.

AI Summary

NanoVibronix, Inc. filed an 8-K on January 6, 2025, reporting on other events and financial statements. The filing details the company's principal executive offices located at 969 Pruitt Ave, Tyler, Texas 77569, and its telephone number as (914) 233-3004. The company was incorporated in Delaware and its fiscal year ends on December 31st.

Why It Matters

This 8-K filing provides essential corporate information and updates for NanoVibronix, Inc., including its address and contact details, which are important for investors and stakeholders to track the company's operational base.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting corporate information and does not contain significant financial or operational news that would inherently increase risk.

Key Players & Entities

• NanoVibronix, Inc. (company) — Registrant
• January 6, 2025 (date) — Date of earliest event reported
• 969 Pruitt Ave, Tyler, Texas 77569 (address) — Address of principal executive offices
• (914) 233-3004 (phone_number) — Registrant's telephone number
• Delaware (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share NAOV Nasdaq Capital Mark
• $1.00 — y did not meet the minimum bid price of $1.00 per share required for continued listin
• $2.5 million — hat the Company no longer satisfied the $2.5 million stockholders' equity requirement set fo

Filing Documents

• form8-k.htm (8-K) — 41KB
• ex99-1.htm (EX-99.1) — 13KB
• 0001493152-25-000385.txt ( ) — 230KB
• naov-20240106.xsd (EX-101.SCH) — 3KB
• naov-20240106_lab.xml (EX-101.LAB) — 33KB
• naov-20240106_pre.xml (EX-101.PRE) — 24KB
• form8-k_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 6, 2025, NanoVibronix, Inc. (the "Company") issued a press release announcing the completion of the first phase of a randomized control trial study of the Company's UroShield by researchers at the University of Michigan. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished pursuant to Item 7.01 and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filing.

01 Other Events

Item 8.01 Other Events. As previously disclosed, on April 10, 2024, the Company received a letter (the "Letter") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon the closing bid price of the Company's common stock, par value $0.001 per share ("Common Stock"), for the 30 consecutive business days between February 27, 2024 and April 9, 2024, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). The Letter also indicated that the Company was provided with a compliance period of 180 calendar days, or until October 7, 2024, in which to regain compliance with the Bid Price Rule pursuant to Nasdaq Listing Rule 5810(c)(3)(A). The Company did not regain compliance with the Bid Price Rule by October 7, 2024, and on October 8, 2024, Nasdaq notified the Company that the Company's securities were subject to delisting from Nasdaq unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the "Panel"). The Company subsequently timely requested a hearing before the Panel, which was held on December 5, 2024 (the "Hearing"). On November 19, 2024, the Company received an additional deficiency notice from the Staff indicating that the Company no longer satisfied the $2.5 million stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule") for continued listing on The Nasdaq Capital Market. The Staff indicated that the Company's non-compliance with the Equity Rule would be considered by the Panel at the Hearing and could serve as an additional basis for delisting of the Company's securities from Nasdaq. The Company announces in this Current Report that the Company received a decision letter from the Panel dated December 26, 2024, granting a limited extension of time to the Company to demonstrate compliance with the Bid Price Rul

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 6, 2025 NANOVIBRONIX, Inc. By: /s/ Stephen Brown Name: Stephen Brown Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR